InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,980.92
(
0.30%
)
Post# of 251798
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119615
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: RioLobo post# 211419

Sunday, 05/21/2017 2:20:10 PM

Sunday, May 21, 2017 2:20:10 PM

Post# of 251798
As of 3/31/17, 40mg Copaxone accounted for >85% of US Copaxone prescriptions, according to TEVA’s 1Q17 PR (http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsarticle&ID=2272193 ).

Is it possible the negative trend mostly reflects competition at 20mg?

No, the split between the branded and generic 20mg products has been pretty stable for several quarters.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up